Paper: Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor “Triplet” Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

IN a retrospective analysis of 87 FLt3 AML patients treated with a FLT3 containing doublet vs triplet regimen at MD Anderson, triplets were associated with increased response rates and overall survival.

Read the full article here

Related Articles